Tessera
Folgen

Matthias Löhr ʚїɞ

@maloehr.bsky.social

Professor of Gastroenterology at #Karolinska Institutet. #Pancreas lover.

186 Posts494 Follower145 Folgt
STITCHES Medicine - the Best of Medical Research@medicine.stitches.today · 4mo ago

Pancreatic neck margin testing offers no survival benefit in pancreatic cancer surgery, highlighting need for clearer clinical guidelines. by Woo KP, Bennett WC (...) Naffouje SA et 13 al. in Ann Surg Oncol #MedSky 👉 get more here 📖 read the article:

The Practices of Pancreatic Neck Margin Testing and Their Outcomes after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma - Annals of Surgical Oncology

Background The role of checking the pancreatic neck margin with frozen section (PNM-FS) during pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) to secure R0 resection and its impact on long-term outcomes remains an area of debate. Patients and Methods Patients with PD for PDAC between 2018 and 2023 were included. The primary outcome was pancreatic neck recurrence-free survival (PN-RFS). Secondary outcomes were locoregional recurrence-free survival (LR-RFS), distant recurrence-free survival (D-RFS), and overall survival (OS). Results There were 403 patients who met inclusion criteria. PNM-FS was checked in 361 patients (89.6.2%) and returned negative at first attempt in 285 (78.9%). A total of 76 patients had positive PNM-FS; 71 were revised and clearance achieved on repeat sampling in 49 (69.0%). Median PN-RFS in patients with PNM-FS cleared with revision was significantly shorter compared with those with negative PNM-FS at first attempt (16.9 versus 23.1 months; p = 0.048) but was not different from patients with PNM-FS not cleared (16.9 versus 16.0 months; p = 0.961). LR-RFS and D-RFS were not different between the groups. OS was marginally longer in patients with negative PNM-FS at first attempt (23.9 versus 19.4 versus 16.0 months; p = 0.049). Six patients underwent completion total pancreatectomy (TP) for margin clearance, four developed distant recurrence, one locoregional recurrence and two died without disease at 1 and 11 months postoperatively. Conclusions PNM-FS is only a prognostic marker. Pursuing PNM-FS clearance does not improve PN-RFS, LR-RFS, D-RFS, or OS. Furthermore, pursuing a completion TP may be associated with shorter OS either from disease progression or surgical morbidity.

link.springer.com

Karolinska Institutet@ki.se · 4mo ago

A new study in Journal of Experimental & Clinical Cancer Research shows that sodium selenite can reinforce epithelial features and dampen EMT-associated plasticity in pancreatic cancer. The effect was dose- and context-dependent in patient-derived tissues. #PancreaticCancer 🧪

Bild
NEJM.org@nejm.org · 5mo ago

In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://nej.md/4fKYQG4 #EULAR2026

A line graph from an article titled "Obexelimab for the Treatment of IgG4-Related Disease," which shows estimates over time of the probability of a first flare of IgG4-related disease for which rescue therapy was required. Below the graph is a footnote detail and the logo for the New England Journal of Medicine.
Nature Reviews Gastroenterology & Hepatology@natrevgastrohep.nature.com · 5mo ago

ICYMI: New online! Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice

Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice

Nature Reviews Gastroenterology & Hepatology, Published online: 20 May 2026; doi:10.1038/s41575-026-01214-8Metabolic dysfunction-associated steatotic liver disease is a leading cause of chronic liver disease, with rising liver transplantation rates. New therapies such as resmetirom and semaglutide mark a shift in treatment. However, identifying suitable patients remains challenging, requiring integrated approaches combining fibrosis stage, metabolic factors and non-invasive tools in real-world practice.

dlvr.it

European Research Council (ERC)@erc.europa.eu · 6mo ago

Are you a researcher based in the USA 🇺🇸 or Canada 🇨🇦 interested in pursuing curiosity-driven research in Europe? Join the ERC and Euraxess for a webinar exploring ERC funding opportunities. 👇️ 📅 20 May 2026 🕚 11:30 AM ET | 8:30 AM PT 💻 Online Find out more and register:

ERC Grants Info Session: Funding for Excellent Frontier Research

Join EURAXESS North America and the European Research Council Executive Agency for a webinar on the bottom-up funding schemes that make up the European Research Council grants. The ERC is the premier…

buff.ly